EINECS 200-291-6 en es it fr

EINECS 200-291-6 Brand names, EINECS 200-291-6 Analogs

EINECS 200-291-6 Brand Names Mixture

  • No information avaliable

EINECS 200-291-6 Chemical_Formula


EINECS 200-291-6 RX_link

No information avaliable

EINECS 200-291-6 fda sheet

EINECS 200-291-6 msds (material safety sheet)


EINECS 200-291-6 Synthesis Reference

No information avaliable

EINECS 200-291-6 Molecular Weight

133.104 g/mol

EINECS 200-291-6 Melting Point

230 oC

EINECS 200-291-6 H2O Solubility

4.5 g/l

EINECS 200-291-6 State


EINECS 200-291-6 LogP

-0.67 +/- 0.36

EINECS 200-291-6 Dosage Forms

Capsules and powder

EINECS 200-291-6 Indication

There is no support for the claim that aspartates are exercise performance enhancers, i.e. ergogenic aids.

EINECS 200-291-6 Pharmacology

L-aspartate is considered a non-essential amino acid, meaning that, under normal physiological conditions, sufficient amounts of the amino acid are synthesized in the body to meet the body's requirements. L-aspartate is formed by the transamination of the Krebs cycle intermediate oxaloacetate. The amino acid serves as a precursor for synthesis of proteins, oligopeptides, purines, pyrimidines, nucleic acids and L-arginine. L-aspartate is a glycogenic amino acid, and it can also promote energy production via its metabolism in the Krebs cycle. These latter activities were the rationale for the claim that supplemental aspartate has an anti-fatigue effect on skeletal muscle, a claim that was never confirmed.

EINECS 200-291-6 Absorption

Absorbed from the small intestine by an active transport process

EINECS 200-291-6 side effects and Toxicity

Mild gastrointestinal side effects including diarrhea. LD50 (rat) > 5,000 mg/kg.

EINECS 200-291-6 Patient Information

No information avaliable

EINECS 200-291-6 Organisms Affected

Humans and other mammals